Showing 3231-3240 of 3314 results for "".
- Kala Pharmaceuticals Announces FDA Approval of Inveltys for the Treatment of Postoperative Inflammation and Painhttps://modernod.com/news/kala-pharmaceuticals-announces-fda-approval-of-inveltys-for-the-treatment-of-postoperative-inflammation-and-pain-following-ocular-surgery/2479913/Kala Pharmaceuticals announced that the FDA has approved Inveltys (loteprednol etabonate ophthalmic suspension 1%) for the treatment of postoperative inflammation and pain following ocular surgery. Inveltys is the first twice-daily (BID) ocular corticosteroid approved for this indication.
- Dompé Receives FDA Approval of Oxervate, the First Drug for Neurotrophic Keratitishttps://modernod.com/news/dompe-receives-fda-approval-of-oxervate-a-first-in-class-treatment-of-neurotrophic-keratitis/2479916/The FDA has approved the first drug to treat neurotrophic keratitis, a rare and progressive eye disease that can lead to corneal scarring and vision loss. Oxervate (cenegermin-bkbj ophthalmic solution), which is manufactured by Italian pharmaceutical company Dompé, is based on cenegermin-b
- Topcon Announces Date for 3rd Annual ISSOCT Conferencehttps://modernod.com/news/topcon-announces-date-for-3rd-annual-issoct-conference/2479931/Topcon Medical Systems has announced that the 3rd Annual ISSOCT Conference will be held on February 10-11, 2019 at the Sanibel Harbour Marriott Resort in Fort Myers, Florida. The world’s leading ophthalmologist
- Bascom Palmer Eye Institute Ranked Nation’s No. 1 in Ophthalmology for 17th Timehttps://modernod.com/news/bascom-palmer-eye-institute-ranked-nations-no-1-in-ophthalmology-for-17th-time/2479945/U.S News & World Report has once again ranked Bascom Palmer Eye Institute of the University of Miami Health System as the nation’s best in ophthalmology. Recognized as a global leader in vision research, medical education and patient care, Basco
- Regeneron Faces Delay to FDA Approval of 12-Week Dosing Schedule for Eylea in Wet AMDhttps://modernod.com/news/regeneron-faces-delay-to-fda-approval-of-12-week-dosing-schedule-for-eylea-in-wet-amd/2479946/Regeneron announced that the FDA issued a complete response letter regarding a filing seeking approval of a 12-week dosing schedule for »Eylea (aflibercept) in patients wit
- Australian Research Lifts the Lid on Lipids to Prevent Dry Eyehttps://modernod.com/news/australian-research-lifts-the-lid-on-lipids-to-prevent-dry-eye/2479951/Australian researchers have made an important breakthrough in understanding the composition of the tear film that protects the eyes, leading to more effective treatments for dry eye disease. The project was a collaboration between researchers at University of Wollongong, QUT and the Univ
- Imprimis Announces Clinical Trial for Dropless TriMoxi Formulation in Canadahttps://modernod.com/news/imprimis-announces-clinical-trial-for-dropless-trimoxi-formulation-in-canada/2479968/Imprimis Pharmaceuticals announced that its Canadian partner, Advanced Dosage Forms, will begin enrolling patients at McGill University Health Centre (MUHC) for a clinical trial of Imprimis’s leading Dropless (triamcinolone acetonide-moxifloxacin) formulation aft
- EyePoint Pharmaceuticals Appoints David Price as Chief Financial Officerhttps://modernod.com/news/eyepoint-pharmaceuticals-appoints-david-price-as-chief-financial-officer/2479969/EyePoint Pharmaceuticals announced the appointment of David Price as Chief Financial Officer, effective immediately. In this role, Mr. Price will oversee and lead the company’s financial and capital markets activities. Mr. Price brings to EyePoint more than 25 years of financial experience
- Visual Function Problems May Be More Common in Children With Dyslexiahttps://modernod.com/news/visual-function-problems-may-be-more-common-in-children-with-dyslexia/2479977/Children with developmental dyslexia (DD) may be more likely to have visual deficits than their typically developing peers, a study suggests, according to a report in Reuters. Nearly 80% of the DD group had a deficit in at least one
- Surgeons from Vance Thompson Vision Make Impact with Mission Trip to Hondurashttps://modernod.com/news/surgeons-from-vance-thompson-vision-make-impact-with-mission-trip-to-honduras/2479985/This spring, Russell Swan, MD, led a team of surgeons from Vance Thompson Vision and the University of Iowa, plus staff members, on a mission trip to Honduras. Russell Swan, MD, John Berdahl, MD, Brandon Baartman, MD, and Dan Bettis, MD, were joined by five team members for a week-long sur